Proteomic Analysis of Human Breast Cancer: New Technologies and Clinical Applications for Biomarker Profiling
- *Corresponding Author:
- Bechr Hamrita
Laboratoire d’Immuno-Oncologie Moléculaire
Faculté de Médecine de Monastir, 5019 Monastir, Tunisia
Tel: +216 73 462 200
Fax: +216 73 230 932
E-mail: [email protected]
Received Date: February 11, 2010; Accepted Date: March 15, 2010; Published Date: March 15, 2010
Citation: Hamrita B, Nasr HB, Chahed K, Kabbage M, Chouchane L (2010) Proteomic Analysis of Human Breast Cancer: New Technologies and Clinical Applications for Biomarker Profiling. J Proteomics Bioinform 3: 091-098. doi: 10.4172/jpb.1000126
Copyright: © 2010 Hamrita B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of breast cancer research, reviving old areas as well as opening new fields of study like early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Breast cancer proteomics has already identified markers of potential clinical interest (such as the molecular chaperone alpha B-crystallin) and technological innovations such as large scale and high throughput analysis are now driving the field. In this review, we discuss the basic features of proteomic technologies, including MS, and we consider the main current applications and challenges of proteomics in breast cancer research, including (i) protein expression profiling of breast tumours, tumour cells, tumour fluids and the auto-immune response of the breast cancer cells. All of these applications continue to benefit from further technological advances, such as the development of proteomics methods, high-resolution, highsensitivity MS, SERPA approach, and advanced bioinformatics for data handling and interpretation.